Tumor Immunotherapy by Gene-circuit Recruited Immunomodulatory Systems (TIGRIS) for Prostate Cancer
Technical Report,01 Sep 2016,31 Aug 2017
Massachusetts Institute of Technology Cambridge United States
Pagination or Media Count:
Immunotherapy has demonstrated robust therapeutic efficacy but is still facing challenges. We aim to build a versatile Tumor Immunotherapy by Gene-circuit Recruited Immunomodulatory Systems TIGRIS for prostate cancer. TIGRIS may overcome major challenges in current tumor immunotherapy. In the research period, we first validated that TIGRIS can trigger robust in vitro and in vivo efficacy in an ovarian cancer model. In addition, we have optimized the required genetic components for building TIGRIS for prostate cancer. We then identified the optimal circuit architecture for TIGRIS. Furthermore, we have created a synthetic promoter library 6000 synthetic cancer sensors that can be used to detect multiple different cancer types. Currently, we have found new sensors that can detect prostate cancers. We will combine these sensors with the optimal circuit architecture and validate the specificity of TIGRIS on distinguish prostate cancers from a panel of normal cells. We will further optimize the circuit to minimize the potential off-target effect on a panel of normal cells. Lastly, we will optimize the multi-output architecture to enable a reliable combinatorial output production from tumor cells.
- Medicine and Medical Research
- Genetic Engineering and Molecular Biology